Chi C Wong
Overview
Explore the profile of Chi C Wong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
678
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wong C, Johnson M
Reprod Biomed Online
. 2014 Aug;
29(2):147-9.
PMID: 25092534
No abstract available.
12.
Mattheolabakis G, Wong C, Sun Y, Amella C, Richards R, Constantinides P, et al.
J Pharmacol Exp Ther
. 2014 Jul;
351(1):61-6.
PMID: 25047517
Esterase hydrolysis of drugs can accelerate their elimination, thereby limiting their efficacy. Polyethylene glycol (PEG) covalently attached to drugs (pegylation) is known to improve the efficiency of many drugs. Using...
13.
Huang L, Wong C, Mackenzie G, Sun Y, Cheng K, Vrankova K, et al.
BMC Cancer
. 2014 Mar;
14:141.
PMID: 24575839
Background: The anticancer properties of aspirin are restricted by its gastrointestinal toxicity and its limited efficacy. Therefore, we synthesized phospho-aspirin (PA-2; MDC-22), a novel derivative of aspirin, and evaluated its...
14.
Wong C, Martincorena I, Rust A, Rashid M, Alifrangis C, Alexandrov L, et al.
Nat Genet
. 2013 Dec;
46(1):33-8.
PMID: 24316979
A major challenge in cancer genetics is to determine which low-frequency somatic mutations are drivers of tumorigenesis. Here we interrogate the genomes of 7,651 diverse human cancers and find inactivating...
15.
Murray O, Wong C, Vrankova K, Rigas B
Int J Oncol
. 2013 Nov;
44(2):521-9.
PMID: 24284479
Phospho-sulindac (P-S), a promising anticancer agent, is efficacious in pre-clinical models of human cancer and is apparently safe. Here, we studied the effect of P-S on pancreatic cancer growth. We...
16.
Cheng K, Wong C, Mattheolabakis G, Xie G, Huang L, Rigas B
Int J Oncol
. 2013 Jun;
43(3):895-902.
PMID: 23807084
Phospho-sulindac (PS) is a safe sulindac derivative with promising anticancer efficacy in colon cancer. We evaluated whether its combination with curcumin could enhance the efficacy in the treatment of lung...
17.
Cheng K, Wong C, Alston N, Mackenzie G, Huang L, Ouyang N, et al.
Mol Cancer Ther
. 2013 May;
12(8):1417-28.
PMID: 23645590
Phospho-sulindac is a sulindac derivative with promising anticancer activity in lung cancer, but its limited metabolic stability presents a major challenge for systemic therapy. We reasoned that inhalation delivery of...
18.
Xie G, Zhou D, Cheng K, Wong C, Rigas B
Biochem Pharmacol
. 2013 Feb;
85(8):1195-202.
PMID: 23399640
Phospho-tyrosol-indomethacin (PTI; MPI 621), a novel anti-cancer agent, is more potent and safer than conventional indomethacin. Here, we show that PTI was extensively metabolized in vitro and in vivo. PTI...
19.
Zhou D, Papayannis I, Mackenzie G, Alston N, Ouyang N, Huang L, et al.
Carcinogenesis
. 2013 Jan;
34(4):943-51.
PMID: 23338686
We have synthesized a novel derivative of indomethacin, phospho-tyrosol-indomethacin (PTI; MPI-621), and evaluated its anticancer efficacy in vitro and in vivo. PTI inhibited the growth of human colon, breast and...
20.
Cheng K, Mattheolabakis G, Wong C, Ouyang N, Huang L, Constantinides P, et al.
Int J Oncol
. 2012 Jul;
41(4):1199-203.
PMID: 22842609
Phospho-sulindac (P-S, OXT-328), a novel sulindac derivative, has shown superior anticancer efficacy and safety compared to sulindac. In this study, we investigated the efficacy of topical P-S hydrogel in the...